Key terms
About QNRX
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest QNRX news
Mar 27
7:03am ET
Quoin Pharmaceuticals price target lowered to $10 from $20 at Alliance Global
Mar 15
8:05am ET
Quoin Pharmaceuticals price target lowered to $4 from $15 at Maxim
Mar 05
8:20am ET
Quoin Pharmaceuticals 4.063M share Secondary priced at $1.60
Mar 04
8:02am ET
Quoin Pharmaceuticals announces FDA clearance to recruit teen subjects
Feb 14
9:08am ET
Skinvisible provides update on ongoing trials conducted by Quoin
Feb 12
5:16pm ET
Quoin Pharmaceuticals files to sell 2.09M ordinary shares, warrants
Feb 08
8:08am ET
Quoin Pharmaceuticals files U.S., international patent application
May 17
4:30am ET
Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome
Mar 24
4:30am ET
Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024
Feb 08
3:30am ET
Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy
QNRX Financials
Key terms
Ad Feedback
QNRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
QNRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
